[1]石 磊,任婷婷,谭 云,等.基于TOUS胰腺癌术后患者症状群与CRF、生活质量的研究[J].医学信息,2024,37(12):179-182.[doi:10.3969/j.issn.1006-1959.2024.12.041]
　SHI Lei,REN Ting-ting,TAN Yun,et al.Study on Symptom Clusters, CRF and Quality of Life of Postoperative Patients with Pancreatic Cancer Based on TOUS[J].Journal of Medical Information,2024,37(12):179-182.[doi:10.3969/j.issn.1006-1959.2024.12.041]
点击复制

基于TOUS胰腺癌术后患者症状群与CRF、生活质量的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年12期
页码:
179-182
栏目:
综述
出版日期:
2024-06-15

文章信息/Info

Title:
Study on Symptom Clusters, CRF and Quality of Life of Postoperative Patients with Pancreatic Cancer Based on TOUS
文章编号:
1006-1959（2024）11-0179-04
作者:
石 磊; 任婷婷; 谭 云; 等
（贵州医科大学附属医院肝胆外科，贵州 贵阳 550001）
Author(s):
SHI Lei; REN Ting-ting; TAN Yun; et al.
(Department of Hepatobiliary Surgery,Affiliated Hospital of Guizhou Medical University,Guiyang 550001,Guizhou,China)
关键词:
胰腺癌; 不悦症状理论; 癌因性疲乏; 生活质量
Keywords:
Pancreatic cancer; Theory of unpleasant symptoms; Cancer-related fatigue; Quality of life
分类号:
R735.9
DOI:
10.3969/j.issn.1006-1959.2024.12.041
文献标志码:
A
摘要:
胰十二指肠切除术是临床常见术式，但术后会出现一系列症候群，加之癌因性疲乏（CRF）影响，进而降低患者生活质量。随着对胰腺癌术后患者症状群的研究，发现系统的症状管理与治疗对提高患者的生活质量具有重要意义。不悦症状理论（TOUS）是症状相关的中域理论之一，通过介绍患者面对不舒适症状时可能出现的身心反应，构建个体症状整体情况，进一步为制定个性化整体治疗方案提供理论基础。但目前TOUS理论主要被应用于肺癌、心衰、乳腺癌、结肠癌等患者，胰腺癌相关研究较少。本文基于TOUS胰腺癌术后患者症状群与CRF、生活质量进行综述，以期为胰腺癌术后患者制定改善临床症状治疗方法提供新的方向。
Abstract:
Pancreaticoduodenectomy is a common clinical operation, but a series of symptoms will appear after operation, coupled with cancer-related fatigue (CRF), which will reduce the quality of life of patients. With the study of symptom clusters in patients with pancreatic cancer after surgery, it has been found that systematic symptom management and treatment are of great significance to improve the quality of life of patients. The theory of unpleasant symptoms (TOUS) is one of the middle domain theories related to symptoms. By introducing the possible physical and mental reactions of patients in the face of uncomfortable symptoms, the overall situation of individual symptoms is constructed, which further provides a theoretical basis for the formulation of personalized overall treatment plans. However, the current TOUS theory is mainly applied to patients with lung cancer, heart failure, breast cancer, colon cancer, etc., and there are few studies on pancreatic cancer. This article reviews the symptom clusters, CRF and quality of life of patients with pancreatic cancer after TOUS, in order to provide a new direction for patients with pancreatic cancer to develop treatment methods to improve clinical symptoms.

参考文献/References:

[1]Kamal M,Wang XS,Shi Q,et al.A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer[J].J Pain Symptom Manage,2020,59(5):1052-1058.e1.[2]van Dijk SM,Heerkens HD,Tseng DSJ,et al.Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer[J].HPB (Oxford),2018,20(3):204-215.[3]周燕梅.癌症患者生命质量测定量表体系之胰腺癌量表QLICP-PA的研制与评价[D].昆明:昆明医科大学,2018.[4]荣华.胰腺切除术后患者短期生活质量的前瞻性观察研究[D].南京:南京大学,2017.[5]中华医学会外科学分会胰腺外科学组,中国研究型医院学会胰腺疾病专业委员会. 胰腺术后外分泌功能不全诊治的中国专家共识(2018)[J].中华外科杂志,2018,56(9):641-645.[6]王务萍,林海燕,钱媛媛,等.淋巴瘤化疗患者癌因性疲乏现状及影响因素分析[J].中华全科医学,2019,17(6):1042-1045.[7]季春晓,于晓娜,张美平,等.淋巴瘤成年患者癌因性疲乏和社会支持与生活质量的关系[J].中国肿瘤临床与康复,2020,27(7):824-827.[8]Christine M,Andrea B,Ann B,et al.Advancing Symptom Science Through Symptom Cluster Research:Expert Panel Proceedings and Recommendations[J].Natl Cancer Inst,2018,109(4):1-9.[9]Tempero MA,Malafa MP,Chiorean EG,et al.Pancreatic Adenocarcinoma,Version 2.2019[J].J Natl Compr Canc Netw,2019,17(3):202-210.[10]Mu?觡oz AR,Chakravarthy D,Gong J,et al.Pancreatic cancer: Current status and Challenges[J].Curr Pharmacol Rep,2017,3(6):396-408.[11]王千心,孙田杰,刘叶,等.乳腺癌术后化疗病人症状群及其影响因素分析[J].护理研究,2019,29(5):556-560. [12]沈颜,季敏慧,藤丹霞,等.止痛药联合认知干预对胰腺癌患者术后生活质量的影响[J].实用肿瘤杂志,2017,32(3):257-259.[13]陈沛,周慧勤,苏侠.灵性护理对胰腺癌术后化疗患者灵性健康水平、癌因性疲乏及睡眠质量的效果评价[J].护理实践与研究,2022,19(2):277-279.[14]潘亚奇.胰腺癌长期生存患者的临床病理特征和生存质量研究[D].上海:中国人民解放军海军军医大学,2020.[15]乔永新.胰腺癌的外科治疗附91例胰腺癌患者临床症状分析[D].石家庄:河北医科大学,2010.[16]Yang S,Ye ZM,Chen S,et al.MicroRNA-23a-5p promotes atherosclerotic plaque progression and vulnerability by repressing ATP-binding cassette transporter A1/G1 in macrophages[J].J Mol Cell Cardiol,2018,123:139-149.[17]章立楠,邵薇娜,赵港美,等.乳腺癌患者化疗后癌因性疲乏调查和正念训练干预临床价值研究[J].中国妇幼保健,2021,36(16):3778-3782.[18]张剑军,钱建新.中国癌症相关性疲乏临床实践诊疗指南（2021年版）[J].中国癌症杂志,2021,31(9):852-872.[19]李沈,王小明,王晓红.淋巴结阳性胰腺癌患者术后生存预测模型的构建[J].右江民族医学院学报,2023,45(2):304-312.[20]谢彧,杭和兴,李刚,等.海德堡胰腺癌预后评分对胰腺癌根治性切除术后病人预后的评估价值分析[J].中国实用外科杂志,2022,42(5):585-589.[21]王媛媛,蒙博,王莹莹.影响胰腺癌切除术后患者预后的相关危险因素分析[J].实用癌症杂志,2023,38(1):142-144,151.[22]徐冬,陆子鹏,郭峰,等.胰腺癌根治术后病人生存相关因素分析[J].中国实用外科杂志,2017,37(7):778-783.[23]安革利,董峰,宋利芳.胰腺癌根治术后患者预后的相关影响因素[J].实用癌症杂志,2023,38(1):126-128,132.[24]应杰萍,成迎春,王跃琴.胰腺癌患者症状群与恐惧疾病进展的相关性研究[J].湖北科技学院学报(医学版),2022,36(1):35-38.[25]杨婷梅.上消化道异位胰腺临床病理特征与其症状相关因素回顾性研究[D].广州:南方医科大学,2019.[26]Tung S,Davis LE,Hallet J,et al.Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma[J].JAMA Surg,2019,154(11):e193348.[27]冯秀娟.基于不悦症状理论的结直肠癌患者癌因性疲乏状况及相关因素[D].济南:山东大学,2019.[28]杨邵真,赵婷鹭.胰腺癌患者主要照顾者的积极感受现状及其影响因素分析[J].福建医药杂志,2023,45(1):140-142.[29]妮娜.基于不悦症理论乳腺癌化疗病人希望、症状负担对生活质量影响研究[D].长春:吉林大学,2019.

相似文献/References:

[1]赵霓姗.胰腺癌主要危险因素及作用机制研究[J].医学信息,2020,33(03):56.[doi:10.3969/j.issn.1006-1959.2020.03.017]
　ZHAO Ni-shan.Study on the Main Risk Factors and Mechanism of Pancreatic Cancer[J].Journal of Medical Information,2020,33(12):56.[doi:10.3969/j.issn.1006-1959.2020.03.017]
[2]张文娟,边 伟,王炳超,等.miR-381在胰腺癌患者组织及外周血的表达及临床价值[J].医学信息,2021,34(06):111.[doi:10.3969/j.issn.1006-1959.2021.06.028]
　ZHANG Wen-juan,BIAN Wei,WANG Bing-chao,et al.The Expression and Clinical Value of miR-381 in Tissues and Peripheral Blood of Patients with Pancreatic Cancer[J].Journal of Medical Information,2021,34(12):111.[doi:10.3969/j.issn.1006-1959.2021.06.028]
[3]王宇路,王苏平,赵雪梅,等.磁共振胰胆管成像对肿块型胰腺炎与胰腺癌的诊断价值[J].医学信息,2021,34(13):176.[doi:10.3969/j.issn.1006-1959.2021.13.049]
　WANG Yu-lu,WANG Su-ping,ZHAO Xue-mei,et al.The Value of Magnetic Resonance Cholangiopancreatography in the Differential Diagnosis of Mass Forming ChronicPancreatitis and Pancreatic Cancer[J].Journal of Medical Information,2021,34(12):176.[doi:10.3969/j.issn.1006-1959.2021.13.049]
[4]邓裕山,沈国双.AP1基因家族与恶性肿瘤的关系研究[J].医学信息,2022,35(06):56.[doi:10.3969/j.issn.1006-1959.2022.06.014]
　DENG Yu-shan,SHEN Guo-shuang.Study on the Relationship Between AP1 Gene Family and Malignant Tumors[J].Journal of Medical Information,2022,35(12):56.[doi:10.3969/j.issn.1006-1959.2022.06.014]
[5]孙惠昕,贾海晗,王婉莹,等.胰腺癌流行现状和影响因素的研究[J].医学信息,2022,35(11):47.[doi:10.3969/j.issn.1006-1959.2022.11.014]
　SUN Hui-xin,JIA Hai-han,WANG Wan-ying,et al.The Prevalence and Influencing Factors of Pancreatic Cancer[J].Journal of Medical Information,2022,35(12):47.[doi:10.3969/j.issn.1006-1959.2022.11.014]
[6]周国斌,柳登平.磁共振和经腹部彩超对胰腺癌与肿块型胰腺炎的鉴别诊断价值分析[J].医学信息,2022,35(17):99.[doi:10.3969/j.issn.1006-1959.2022.17.026]
　ZHOU Guo-bin,LIU Deng-ping.Value of Magnetic Resonance and Transabdominal Ultrasonography in Differential Diagnosis of Pancreatic Carcinoma and Mass-type Pancreatitis[J].Journal of Medical Information,2022,35(12):99.[doi:10.3969/j.issn.1006-1959.2022.17.026]
[7]漆处梅,唐小龙.胰腺癌患者BZW1和BZW2表达水平及其与预后的相关性分析[J].医学信息,2022,35(21):26.[doi:10.3969/j.issn.1006-1959.2022.21.006]
　QI Chu-mei,TANG Xiao-long.Expression of BZW1 and BZW2 in Pancreatic Cancer and its Correlation with Prognosis[J].Journal of Medical Information,2022,35(12):26.[doi:10.3969/j.issn.1006-1959.2022.21.006]
[8]王雨娜,吴冬桂,赵 贝.基于数据挖掘AGR2在胰腺癌中的表达及预后潜力[J].医学信息,2022,35(22):9.[doi:10.3969/j.issn.1006-1959.2022.22.002]
　WANG Yu-na,WU Dong-gui,ZHAO Bei.Expression and Prognostic Potential of AGR2 in Pancreatic Cancer Based on Data Mining[J].Journal of Medical Information,2022,35(12):9.[doi:10.3969/j.issn.1006-1959.2022.22.002]
[9]刘 基,孙振纲,邓 岩,等.炎症对胰腺癌患者预后的评估及免疫状态的影响[J].医学信息,2023,36(05):13.[doi:10.3969/j.issn.1006-1959.2023.05.003]
　LIU Ji,SUN Zhen-gang,DENG Yan,et al.Effects of Inflammation on Prognosis and Immune Status in Patients with Pancreatic Adenocarcinoma[J].Journal of Medical Information,2023,36(12):13.[doi:10.3969/j.issn.1006-1959.2023.05.003]
[10]卢 琪,尹富生,兰 凯.PI3K/AKT/mTOR通路与胰腺癌发生发展及治疗的研究[J].医学信息,2025,38(02):184.[doi:10.3969/j.issn.1006-1959.2025.02.037]
　LU Qi,YIN Fusheng,LAN Kai.Role of PI3K/AKT/mTOR Pathway in the Development and Treatment of Pancreatic Cancer[J].Journal of Medical Information,2025,38(12):184.[doi:10.3969/j.issn.1006-1959.2025.02.037]

更新日期/Last Update: 1900-01-01